Clinical trial and in vitro study investigating topical

application of Zataria multiflora Boiss. and Matricaria

chamomilla extracts for androgenetic alopecia by Sharifan, Anoosheh et al.
Sharifan et al., Cogent Medicine (2017), 4: 1421405
https://doi.org/10.1080/2331205X.2017.1421405
DERMATOLOGY | RESEARCH ARTICLE
Clinical trial and in vitro study investigating topical 
application of Zataria multiflora Boiss. and Matricaria 
chamomilla extracts for androgenetic alopecia
Anoosheh Sharifan1*, Ashraf Hajhoseini2 and Mahdi Bakhtiari3
Abstract: This study was intended to evaluate the hair growth activity of Zataria 
multiflora Boiss. (ZM) and Matricaria chamomilla (MC) for androgenetic alopecia 
following a six-month clinical trial. In vitro studies were conducted to measure 
the inhibitory effects of MC and ZM against 5α-reductase (5αR). In this regard, five 
samples were prepared: NADPH + enzyme + testosterone + extract (n = 2); enzyme 
blank (n = 1); positive and negative controls (n = 2). Thereafter, 60 patients with 
androgenetic alopecia were recruited from Imam Khomeini Hospital, Tehran, Iran. 
They were divided in a 1:1:1 ratio to Groups A, B, and C. The first two were instructed 
to use the topical extract twice daily for three months. Group C was treated with 
placebo in the same instruction. All groups also received 5% topical minoxidil. The 
outcome measures were patch size, terminal hair count, and grown hair count. No 
complications were observed during the treatment. There were significant improve-
ments in the patch size and terminal hair count of Groups A and B as compared with 
those of Group C (p < 0.05). Moreover, the non-considerable promotion of grown hair 
count showed possible synergistic effects. It could be concluded that ZM and MC 
extracts can afford to enhance hair growth by inhibiting the 5αR activity and might 
thus be potent antiandrogen agents.
Subjects: Plant Biotechnology; Alternative Therapy; Costume, Hair and Makeup
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1. Introduction
Steroid-5α-reductase (5α-R) as an androgen metabolizing enzyme exerts its cellular influence to 
adjust paramount processes associated with the prostate, such as the NADPH-dependent local 
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conversion of testosterone to the more potent androgen dihydrotestosterone (DHT) (Krieg, Weisser, 
& Tunn, 1995; Levy et al., 1995). It has been demonstrated that high levels of DHT are correlated to 
different medical conditions, namely prostate carcinogenesis, benign prostatic hyperplasia, andro-
genetic alopecia, hirsutism, acne, male pattern of baldness, and seborrhoea (Dallob et al., 1994; 
Geller, 1992; Labrie, Belanger, Simard, Labrie, & Dupont, 1993; Sansone & Reisner, 1971; Tolino et al., 
1996; Zouboulis et al., 1998). Androgenetic alopecia is considered as the main kind of scalp hair loss 
irrespective of gender (Jain & De-Eknamkul, 2014). This medical condition is becoming a paramount 
issue across the globe, with 30–50% of men being afflicted by age 50. Besides, it comes about in a 
highly reproducible pattern, greatly involving the temples, vertex and mid frontal scalp. However it 
mostly appears as a virtually minor dermatological condition, hair loss carries adverse effects on 
self-image and accounts for anxiety and depression in a number of men. Of note, it can affect the 
likelihood of arterial stiffness and cardiovascular disease. It has been documented that elevated 
androgen levels not only end up with androgenetic alopecia, but also account for atherosclerotic, 
thrombosis, and coronary heart disease (Mansouri, Mortazavi, Eslami, & Mazinani, 2005; Sharma, 
Dubey, Gupta, & Agrawal, 2013; Sharma & Jindal, 2014). The predisposing factors to androgenetic 
alopecia include a familial tendency and race (Cranwell & Sinclair, 2000/2016). An epidemiological 
study was found androgenetic alopecia as the second prevalent skin disorder in northern Iran 
(Hajheydari & Golpour, 2007). Therefore, 5α-R appears promising for treating such disease through 
suppression of DHT synthesis (Brawley, 2003; Lieberman, 2003). Two distinct isozymes – termed type 
I (5α-RI) and type II (5α-RII) – are identified with different biochemical features, tissue distribution 
patterns as well as respond to pharmaceutical agents (Andersson, Berman, Jenkins, & Russell, 1991; 
Andersson & Russell, 1990; Li, Chen, Singh, Labire, & Labire, 1995). As 5α-R type II is the chief isoform 
in human prostate, selective anti-androgenic agents might yield good outcomes for the treatment 
of DHT. Finasteride and minoxidil are widely-used drug candidates as a 5α-R inhibitor across the 
globe. Nevertheless, they has shown multiple undesirable effects. Phytogenic substances for 5α-R 
inhibition might be a key addressing this problem.
Zataria multiflora Boiss. (ZM) (synonyms: Avishan-e-Shirazi in Persian, Thyme in English; ID: 
K000193689 at Royal Botanic Gardens, Kew) from the Lamiaceae family distributes geographically 
in central and southern Iran, Pakistan and Afghanistan (Hosseinzadeh, Ramezani, & Salmani, 2000). 
It has been shown that ZM has notable antinociceptive, antimicrobial, spasmolytic and anti-inflam-
matory potentials. This plant has been recently available in the form of oral drops, soft capsules and 
vaginal creams for special medical necessities. ZM was associated with the oxidative stress and 
genotoxicity arising from cyclophosphamide in mouse bone marrow cells (Hosseinimehr et al., 
2011). Moreover, it has been reported that ZM is composed of phenolic compounds mainly carvacrol 
(Gupta & Gupta, 1972). In this regard, (Saleem, Nazli, Afza, Sami, & Ali, 2004) identified thymol as the 
chief constituent of the fresh plant (73.21%) whereas the dried plant substantially contains carvac-
rol (62.87%). The Labiatae family is reported to be used for hair loss traditionally (Naghibi, Mosaddegh, 
Mohammadi Motamed, & Ghorbani, 2010). Bahney (2009) utilized a remedy containing Rosemary, 
Thyme, Lavender, and CedarWood to stimulate hair growth.
On the other hand, Matricaria chamomilla L. (MC) (synonyms: Babooneh in Persian, Chamomile in 
English) extends all the world around from Europe in Germany and Hungary to North Africa, Asia, 
North and South America, Australia, and New Zealand (Ivens, 1979). It contains a great breadth of 
therapeutically active compounds such as sesquiterpenes, flavonoids, coumarins, and polyacety-
lenes (Schilcher & Kamille, 1987). As many as 11 phenolic constituents were characterized in chamo-
mile extract (Gupta, Mittal, Bansal, Khokra, & Kaushik, 2010). It has been vastly applied for medicinal 
purposes such as selective COX-2 inhibitor owing to its anti-inflammatory, antimicrobial, antioxi-
dant, antiplatelet, chemopreventive potentials (Duke, 2001; McKay & Blumberg, 2006; Srivastava, 
Pandey, & Gupta, 2009). Gowda, Farooqi, Subbaiah, and Raju (1991) reported that the essential oil 
taken from MC heads includes azulene which can have applications in perfumery, cosmetic creams, 
hair preparations, and the like. Additionally, the use of MC has been recommended in scalp burnout 
to wash hair due to its anti-irritant activity (Trüeb, 2015).
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Despite the extant evidence in favor of protective effects of MC and ZM on hair, the scientific basis 
and clinical outcomes are yet to be explored. With a view towards plant-derived 5α-R inhibitors, we 
attempted to investigate two indigenous herbs of Iran for their potential against 5α-RII in both in 
vitro and clinical settings.
2. Materials and methods
2.1. Preparation of extracts
Two plants were purchased from local grocery stores in Tehran, Iran. They were subsequently identi-
fied by comparison with those raised in the Medical Plant Farm, Jahad Daneshgah, Islamic Republic 
of Iran. The plant names have been checked with www.theplantlist.org. A voucher specimen for 
each of them has been deposited in the Herbarium of the Department of Pharmacology, Jahad 
Daneshgah, Tehran, Iran. The aerial parts of the plants were used in the study. The extraction was 
performed with 100 mL of ethanol (Merck, Germany, 96%) in triplicates. The extract was then main-
tained in sealed dark vials at 4°C (Sarikurkcu, Targan, Ozer, & Tepe, 2017). Chemical profile of each 
species was provided as supplementary data. The phenolic content of each extract was measure by 
the Folin–Ciocalteu reagent assay (Azimi, Sharifan, & Ghiasi Tarzi, 2017). The total phenols were 
measured 5.5 ± 0.1 and 11.1 ± 0.4 mg GAEs/g extract for MC and ZM, respectively.
2.2. Enzyme inhibition activity
Enzyme inhibition assay was performed using Sun, Zheng, and Feng’s (1998) method. Initially, a 
certain amount of human prostate was provided from Imam Khomeini hospital in Tehran, and then 
cut into very small pieces. A 10 mL of medium containing 20 mM sodium phosphate (Sigma-Aldrich, 
USA), 0.32M sucrose (Sigma-Aldrich, USA) and 1 mM ethylenediamine tetraacetic acid (EDTA; Sigma-
Aldrich, USA) was mixed with the prostate pieces to yield a homogenate. Thereafter, centrifugation 
was carried out in duplicate at 4000 rpm for 15 min. The ultimate supernatant underwent Bradford 
method to gauge the concentration of enzyme (Bradford, 1976). The results indicated that the con-
centration of 5αRII was 372.38 μg/mL. Study reactions were prepared through mixing a 3 mL of 
nicotinamide adenine dinucleotide phosphate (NADPH; Sigma, USA, 22 μM), 1 mL of enzyme, 4 mL of 
Tris–HCl buffer (Sigma, USA, 0.5 M), 2 mL of testosterone (Sigma, Germany, 75 μM), and 2 mL of eth-
anolic extracts (1 mg/mL). All the samples were analyzed using spectrophotometer at 340 nm. The 
time interval between measurements was 10 min for a period of 30 min. Along with study reactions, 
an enzyme blank, a negative control (2 mL of testosterone added to the blank), and a positive con-
trol (2 mL of 200 nM finasteride added to the negative control) were considered to calculate antioxi-
dant capacity of the extracts (Nahata & Dixit, 2014).
2.3. Participants
In light of 5α-reductase inhibitory activity of MC and ZM, their clinical effectiveness was investigated 
to not only validate the in vitro results, but also to assess their therapeutic potentials as an andro-
genic agent. In this randomized controlled trial with 3 months of intervention with the ethanolic 
extracts. The protocol for this treatment was given approval by the Ethical Committee for Medical 
Research affiliated to Shadara Caspian Company. Moreover, written informed consent was obtained 
from all patients. This trial has conformed to the CONSORT guidelines. As many as 60 subjects were 
enrolled between December 2016 and January 2017 based on the pattern of hair loss and trichos-
copy assessment. This study included those participants who were at least 20 years (at the time of 
assessment); possessed an overall hairless extension of patches below 10 cm²; were currently in-
volved occurrence in androgenetic alopecia (≤10 years) based on Hamilton criterion. The reason why 
this classification for the male pattern was used is because it was also employed in a cross-sectional 
study for Iranian population (Kheirabadi, Yazdani, & Golfam, 2013). If participants underwent an-
tiandrogen therapy or any drug influencing alopecia (Aminosalicylic acid, Enalapril, Amphetamines, 
Etretinate, Bromocriptine, Levodopa, Captopril Lithium, Carbamazepine, Metoprolol, Cimetidine, 
Propanolol, Coumadin, Pyridostigmin Danazol, Trimethadione and valproate sodium), they were al-
lowed to continue this regimen prior to randomization. Short message service text messaging and 
phone calls were daily utilized to enhance patient’s adherence. Allergy to chamomile or thyme, 
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taking steroids or hormonal medication, any significant failure or serious dermatological and neuro-
logical complications in previous antiandrogen therapy, and participation in another androgenic-
based intervention would exclude them from trial recruitment.
2.4. Study intervention
Following the assessment of participant’s eligibility, they were divided into 1:1:1 ratio to Groups A, B 
and C on random. The first two groups were respectively treated with the MC and ZM extracts. The 
last group served as the control to receive placebo. All the treatments were rubbed on the patches 
two times a day. Moreover, the extracts and placebo were the same in terms of color, odor, and size. 
All groups underwent treatment with 5% topical minoxidil twice a day, as well. Randomization was 
carried out using random number table. In this study, hairlessness was considered as the outcome 
measure. This scoring system describes each participant’s condition on the basis of the size of patch-
es, total number of grown hair, and number of terminal hair. The study dermatologists who were 
blinded to group allocation were supposed to collect the data.
2.5. Statistical analysis
Data was described as mean ± standard deviation (SD). Given normal distribution, one-way ANOVA 
and t-test were performed to determine any significant difference at p-values <0.05 (SPSS 19.0, IBM 
Inc., USA). If the normality assumption was violated, the nonparametric Kruskal-Wallis ANOVA was 
used instead. All analyses in the randomized clinical trial were performed according to an intention-
to-treat. A one tailed analysis was used to demonstrate the significant differences in hairlessness at 
p < 0.05.
3. Results
Two plants with vast applications in cuisine and traditional medicine by the Iranian were utilized to 
test their enzyme inhibitory activities. The ethanol-based extraction procedure resulted in extract 
yield of 3.42 and 3.70% for MC and ZM, respectively. Plant species were also examined for their in-
hibitory potentials on 5αRII (Figure 1). On the whole, the inhibitory enzyme activity was on the nota-
ble rise during 30 min (p < 0.05). In the case of plant genera, an influential disparity was observed at 
10 and 20 min (p = 0.01). That is, MC and ZM showed a different potency against 5αRII, with ZM being 
stronger. This test demonstrated the superiority of ZM at 30 min (15.01 ± 0.06 μg/mL). Having confi-
dence in the antiandrogen activity of CM and ZM, 60 patients with androgenetic alopecia were en-
rolled upon inclusion criteria. The study groups were instructed to apply the distinct treatments 
Figure 1. Enzyme inhibitory 
activity of the ethanol extracts 
at 10, 10, 30 min (μg/mL; 
mean ± SD).
Notes: *p-value < 0.05; 
**p-value = 0.01.
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twice a day for three months (Group A: CM + minoxidil; Group B: ZM + minoxidil; Group C: place-
bo + minoxidil). These patients were recruited from Imam Khomeini Hospital, Tehran Iran. As can be 
seen in Table 1, all patients were male with a mean age of 40.3 ± 12.5 years. A third of patients 
served as a control (Group C). It was revealed that the demographic characteristics of the partici-
pants were comparable across three groups (p > 0.05). Table 2 summarized the results of between 
and within group comparisons of hairlessness. Overall, 3-month exposure to antiandrogen therapy 
with topical minoxidil or its combination with MC and ZM caused a significant difference in pre- and 
post-test values of patch size, terminal hair, and grown hair (p < 0.001). On the other hand, no sig-
nificant difference was reported between the three groups at baseline (p > 0.05). Conversely, the 
treatment with the herbal extracts was associated with a notable disparity among the three groups 
in terms of patch size (p = 0.02) and terminal hair count (p = 0.00). However, the grown hair count 
did not differ significantly among them (p = 0.38). Paired comparisons indicated a marked improve-
ment in the values of patch size in Group B when compared with the control (p = 0.01). Besides this, 
Group A presented an insignificant decrease in patch size (p > 0.05). Moreover, the ethanol extracts 
of MC and ZM substantially increased the number of terminal hair in Groups A and B in comparison 
with the control (p < 0.001) (Table 3).
Table 2. The hairlessness scores at baseline and three months
†Kruskal–Wallis ANOVA.
‡ANOVA.
§The difference of hairlessness between pre- and post-test.
Variable Result by study group
Group A Group B Group C p-value
Mean patch size (SD) Baseline 3.6 (0.8) 3.5 (0.9) 3.2 (0.8) 0.45†
3 months 3.1 (0.5) 2.7 (0.3) 3.2 (0.7) 0.02†
<0.001§
Mean number of terminal hair (SD) Baseline 4.1 (2.5) 3.3 (2.6) 3.5 (2.6) 0.53†
3 months 24.6 (3.7) 38.1 (5.9) 14.5 (3.5) 0.00†
<0.001§
Mean number of grown hair (SD) Baseline 13.7 (10.2) 14.00 (10.4) 16.5 (12.8) 0.69‡
<0.001§
3 months 19.1 (9.4) 21.6 (11.9) 18.0 (12.3) 0.38†
<0.001§
Table 1. Patient’s demographics at baseline
Variables Group A (n = 20) Group B (n = 20) Group C (n = 20) p-value
Mean age, years (SD) 41.6 (14.2) 40.7 (10.1) 38.6 (12.8) 0.11
Mean history of hair loss, years 
(SD)
5.3 (1.7) 4.9 (1.4) 5.6 (1.0) 0.07
Pattern of hair loss (%) 0.24
 Step 1 11 (55.0) 9 (45.0) 11 (55.0)
 Step 2 4 (20.0) 2 (10.0) 2 (10)
 Step 3 3 (15.0) 4 (20.0) 2 (10)
 Step 4 1 (5.0) 2 (10.0) 1 (5)
 Step 5 0 (0.0) 2 (10.0) 1 (5)
 Step 6 0 (0.0) 1 (5.0) 1 (5)
 Step 7 1 (5.0) 0 (0.0) 2 (10)
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4. Discussion
With focus on the pathophysiology of androgenetic alopecia, there have been two FDA-approved 
drugs (i.e. minoxidil and finasteride) commonly used by men. Despite the extant evidence in favor of 
their antiandrogenic protection against hair loss, a host of men have voiced concern on sexual dys-
function and feminization (Santos, Avci, & Hamblin, 2015). As a result, botanical extracts have gar-
nered much attention due to their manageable or no side effects. For instance, Eclipta alba and 
Polygonum multiflorum are two plant species which were traditionally utilized for the treatment of 
baldness and hair loss in East Asia. Animal trials have shown that the methanol extract of E. alba as 
well as P. multiflorum extract in water can afford to promote hair growth through increases in ana-
gen-phase hair follicle (Datta et al., 2009; Park, Zhang, & Park, 2011). In this regard, Zhang, Park, and 
Park (2013) reported the antiandrogen properties of Thuja orientalis extract through its inhibitory 
action against 5α-R. In this study, considering the potent role of MC and ZM as antiandrogen agents 
in the experimental section, their combination with topical minoxidil was used as a treatment ap-
proach for androgenetic alopecia in the clinical context. The rational beyond using MC and MC arises 
from the contribution of phenolic content and numerous documentation of in vitro as well as in vivo 
studies highlighting the negative effects of phenolic compounds on the level of 5α-R (Hiipakka, 
Zhang, Dai, Dai, & Liao, 2002; Kumar, Chaiyasut, Rungseevijitprapa, & Suttajit, 2011; Kuroyanagi, 
Arakawa, Hirayama, & Hayashi, 1999; Lee, Chattopadhyay, Gong, Ahn, & Lee, 2003; Paris et al., 
2002). In the ethanol extract of MC and ZM, the presence of phenolic compounds was substantiated 
by the Folin–Ciocalteu reagent assay. As the results demonstrated, ZM had a higher content of phe-
nols than MC while the in vitro phase was determined the stronger inhibitory activity of ZM against 
5α-R. This finding was also evident in the clinical trial where the patients in Group B were found with 
marked improvements in hairlessness.
The results of this investigation came up with other two outcomes; time had a statistically positive 
impact on the progress of enzyme inhibition, which was in broad agreement with Nahata and Dixit’s 
(2014) findings. Also, antiandrogen therapy in all the study patients increased the number of grown 
hair and terminal hair, and yet decreased the patch size at months 1, 2, and 3 (data not shown). 
Therefore, the antiandrogen potential of MC and ZM was evidenced by the inhibition of 5α-R and 
promotion of hair growth in experimental and clinical phases, respectively; pairwise comparisons 
were indicative of remarkable synergism between the botanical extracts as well as topical minoxidil 
in Groups A and B at enhancing hair growth by patch size and terminal hair count. Although there 
was no statistically significant difference in the number of grown hair among the three groups, ad-
ditive therapeutic improvements were obvious in the values of Groups A and B.
Strength of this study regards its design where the rigorous statistical analyses were performed on 
the experimental and clinical data to elucidate the interventional relationship between high antian-
drogen activity and enhanced hair growth. Moreover, the results of the clinical trial were accom-
plished in an approximately long-term follow-up without any missing outcome data. When it comes 
to limitation, we cannot apply a dose-dependent treatment due to the participants’ gender. 
Accordingly, a dose-dependent study would be in the interest of the reader to add more information 
Table 3. The difference of hairlessness among Groups A, B, and C at 3 months
Paired comparisons p-value
Patch size Terminal hair
Group A Group B 0.40 <0.001
Group C 0.86 <0.001
Group B Group A 0.40 <0.001
Group C 0.01 <0.001
Group C Group A 0.86 <0.001
Group B 0.01 <0.001
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concerning the plants. In conclusion, this was the first randomized clinical trial aiming at the rela-
tionship between the antiandrogen activities of these botanical extracts naturally rich in phenols on 
the hair growth of patients with androgenetic alopecia in Iranian adults. This study indicated that 
MC and ZM possessed quite strong anti-androgenic potentials to inhibit 5α-R activity at each time 
point during the in vitro phase. Moreover, it demonstrated an interventional association of plant-
based antiandrogen activity with androgenetic alopecia hairlessness.
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